TABLE 3.
Treatment‐emergent adverse events (TEAEs) in >10% of patients in Part 2 of the study (n = 30)
| Preferred term | All grades, n (%) | Grade ≥ 3, n (%) a |
|---|---|---|
| Any TEAE | 30 (100) | 19 (63.3) |
| Fatigue | 10 (33.3) | – |
| Dysphagia | 7 (23.3) | 2 (6.7) |
| Constipation | 6 (20.0) | – |
| Erythema | 6 (20.0) | – |
| Peripheral edema | 6 (20.0) | – |
| Anemia | 5 (16.7) | 3 (10.0) |
| Dehydration | 5 (16.7) | – |
| Facial edema | 5 (16.7) | 1 (3.3) |
| Rash | 5 (16.7) | – |
| Facial pain | 4 (13.3) | – |
| Oral pain | 4 (13.3) | 2 (6.7) |
| Tumor pain | 4 (13.3) | 2 (6.7) |
| Tongue edema | 4 (13.3) | – |
| Local swelling | 4 (13.3) | – |
| Cough | 4 (13.3) | – |
| Oropharyngeal pain | 4 (13.3) | – |
| Pneumonia | 4 (13.3) | 2 (6.7) |
| Weight decreased | 4 (13.3) | – |
Abbreviation: TEAE, treatment‐emergent adverse event.
a
Other Grade ≥ 3 TEAEs occurring in two patients (6.7%): application site pain, localized edema, hyponatremia, and tumor hemorrhage.